BCL2 and melanoma: Since malignant melanoma is characterized by a poor prognosis and resistance to agents inducing apoptosis, the ability of EcTI to reduce BCL-2 and increase BAX confers on these protein-relevant characteristics to sensitize cancer cells to death.